Title: Plan for Approach to the Understanding and Predicting Excipient Properties and Functionality NIPTE - National Institute of Pharmaceutical Technology.

Slides:



Advertisements
Similar presentations
National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report.
Advertisements

Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
1 Introduction to modeling Process modelling. 2 Where are we? #TitleDate 1Introduction ORM modeling Relational modeling
The NIPTE-FDA Excipients Database hosted at pharmaHUB Ann Christine Catlin Rosen Center for Advanced Computing Purdue University June 14, 2012.
Optimal Design Laboratory | University of Michigan, Ann Arbor 2011 Design Preference Elicitation Using Efficient Global Optimization Yi Ren Panos Y. Papalambros.
Formulation design Manufacturing process design Virtual patient population (PBPK, PDPK) API physical properties Dosage parameters Target.
How to Define Design Space Lynn Torbeck. Overview Why is a definition important? Definitions of Design Space. Deconstructing Q8 Definition. Basic science,
Division of Pharmaceutical Analysis Research in support of the Critical Path Dimensions Ensuring Safety Demonstrating Medical Utility Industrialization.
Polymorphs in Pharmaceutical Products
Determine impurity level in relevant batches1
Pharmtech Contract Services Offered by the Division of Pharmaceutical Technology.
Quality by Design (QbD) in Product Development
The Experience Factory May 2004 Leonardo Vaccaro.
Computational Methods for Management and Economics Carla Gomes Module 3 OR Modeling Approach.
Drying in the Pharmaceutical Industry1 DIT- Msc Pharmaceutical and Chemical Processes Technologies 28 th April 2009 Sara Baeza.
Introduction and Overview “the grid” – a proposed distributed computing infrastructure for advanced science and engineering. Purpose: grid concept is motivated.
Training Guide. The Punch Out Catalog System The Punch Out shopping catalog for VWR takes the user directly into the vendor’s website and online catalog.
User Interface Testing. Hall of Fame or Hall of Shame?  java.sun.com.
Business Driven Enterprise Architecture Assessment Methodology Josh Arceneaux August 16, 2011.
MyFlashcard —A facebook application with multiple purposes Aobo Wang 1.
FAA Regulatory Policy for Composite Material Control Presented at 8/8/02 FAA/NASA Workshop (Chicago, IL) Introduction – Importance of stabilizing composite.
Customizing the Content: The placeholders in this poster are formatted for you. Type in the placeholders to add text, or click an icon to add a table,
VALIDATION OF RAW MATERIALS
MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.
PHUBpk: Pharmacokinetics on the pharmaHUB Stephen D. Stamatis 1, Michael J. McLennan 2, and Lee E. Kirsch 1 HUBbub The University of Iowa College.
Statistical Natural Language Processing. What is NLP?  Natural Language Processing (NLP), or Computational Linguistics, is concerned with theoretical.
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
How characterization of excipient physical and chemical properties helps build quality into drug product Dr Brian A Carlin FMC BioPolymer.
B. Neidhart, W. Wegscheider (Eds.): Quality in Chemical Measurements © Springer-Verlag Berlin Heidelberg 2000 D. RuddThe Importance of “Good” Measurements.
Application of the principles of QbD in vaccines production Andrea Pranti.
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Excipient QbD Concepts to Enhance the Development of Robust Drug Products Priscilla S. Zawislak Global Regulatory Affairs Manager - Ashland Inc. Chair.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Fluid Bed Drying Small.
Applications of Analytical Chemistry in Pharmaceuticals Corey M. Chong 10Mar10.
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Preliminary Design Space 1.
OM: if PS is small, add diluent and use blend style Final Formulation: calculate capsule size, % excipients, and final formulation DF: choose excipients.
Affordable Sources for Property Data Authors: Carrie Newsom Susan K. Cardinal Last Updated: 3/20/07 A product of the ACS CINF Education Committee.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
What Impact should ICH Q8 have on ICH Q6A Decision Trees?
Molecule-to-Market-Place Quality
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
Excipient Composition and Performance-Related Properties of Excipients Chris Moreton, Ph.D. FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
Excipient Variability Sources, Importance and Potential Impact Chris Moreton, Ph.D Past Chair IPEC-Americas Partner – FinnBrit Consulting
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Bioavailability of Dietary Supplements: Key Issues in Defining the Research Agenda Impact of Formulation on Bioavailability? Discussion Leader: Stephen.
T EST T OOLS U NIT VI This unit contains the overview of the test tools. Also prerequisites for applying these tools, tools selection and implementation.
Presented by the GMU Win-Win Team March 17, 2004 Status Report.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
Knowledge Transfer Networks Accelerating business innovation; a Technology Strategy Board programme Review of Challenges in Modelling and HT Methods for.
User Working Group 2013 Crowdsourcing for Dataset Selection 12 March 2013
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University
Foods – dynamic systems Structure variation –Storage –Distribution –Preparation Factors –Composition –Acidity –Internal pressures –Interacting phases –Environmental.
Material Characterization and Control and Knowledge Management Considerations for Continuous Manufacturing with the Real-Time Release Material Characterization.
Proposal for a Manufacturing Classification System (MCS)
Introduction To DBMS.
By Arijit Chatterjee Dr
Results and Discussion
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
WHO Technical Report Series, No. 953, 2009
Dr Dehghan M. H Professor in Pharmaceutics,
Quality by Design.
Presentation transcript:

Title: Plan for Approach to the Understanding and Predicting Excipient Properties and Functionality NIPTE - National Institute of Pharmaceutical Technology and Education Excipient Database Development Project August 15, 2011 update

Today’s Agenda  Introductions  Database overview  PharmHub overview & database demonstration  Test methods overview  Feedback summary – Wish list for features – Future steps

NIPTE Participants NIPTE PersonnelAffiliationRole Stephen W. Hoag Ting Wang University of Maryland, Baltimore School of Pharmacy PI Data collection Data modeling Carl Wassgren Kristine Alston Purdue University Dept. of Mechanical Engineering Data collection Data modeling Ann Christine Catlin Sumudinie Fernando Sudheera R. Fernando Purdue University Rosen Center for Advanced Computing Database technology and development Hub Cyber Infrastructure Linas MockusNIPTE/PurdueDatabase data entry development Prabir BasuNIPTEDirector of NIPTE Administrative

Raw Material Inputs → CQA Critical Quality Attributes Hardness Disintegration time Dissolution CU/mixing Excipient Properties Crystal form Particle size Bulk density Etc. Relationships Not well understood

Excipient Variability Process Step Design Space Inputs Process Parameters Inputs Materials API Excipients Product (or Intermediate) Product Variability Process Variability Unforeseen/unknown excipient variability at the heart of many surprise product failures during production

Excipient Characterization  Key issues – Measurement variability sources  Method differences  Technique differences  Test conditions – Excipient variability  Within supplier  Between suppliers – Critical Quality Attributes (CQA) not always known  E.g., degree of substitution of HPMC – Surface area of Mg Stearate – Unknown factors Trying to account for in database Trying to catalog in database

Development Strategy  Won’t solve problem of excipient functionality with one project – Thus, focus on first step which is material properties of excipients  Goal to develop database infrastructure with finite resources  Start with DC and will expand to other categories as database grows – Current properties  Chemical Description  Flow  Compactability

PH-200 PH-102 SCG PH-102 PH-101 PH-105 PH-103PH-113 PH-112 Decrease moisture content NMT 1.5% NMT 2% NMT 3% NMT 5% Particle size 180 um 150 um 100 um 50 um 20 um PH-302 PH g/cc 0.4g/cc Loose bulk density Increase stability of moisture-sensitive drugs NMT= not more than Comparison of different grades of MCC Increase flow Increase batch size FMC

Comparison of different grades from different manufacturers--MCC ManufacturesGrades Particle Size, µm Moisture, % Loose Bulk Density, g/cc FMCAvicel PH JRS Vivapur Emcocel 50M AKC PH UF KG KG FMCAvicel PH JRS Vivapur Emcocel 90M AKCPH FMC = FMC BIOPOLYMERS AKC = Asahi Kasei Corporation JRS = J Rettenmaier & Söhne GmbH and Co.KG

Database Structure Excipients - MCC Products - PH101 Lots - Lot # 1 Properties - particle size Test method - Light scattering Equipment - Malvern ← USP compendial category ← Actual product on the market

Handbook of Excipients  Handbook of excipients – 1. Nonproprietary Names – 2. Synonyms – 3. Chemical Name and CAS Registry Number – 4. Empirical Formula and Molecular Weight – 5. Structural Formula – 6. Functional Category – 7. Applications in Pharmaceutical Formulation or Technology – 8. Description – 9. Pharmacopeial Specifications – 10. Typical Properties  Angle of repose  Density (bulk, tapped and true)  Flowability  Melting point  Moisture content  NIR spectra  Particle size distribution  Solubility – 11. Stability and Storage Conditions – 12. Incompatibilities – 13. Method of Manufacture – 14. Safety – 15. Handling Precautions – 16. Regulatory Status – 17. Related Substances – 18. Comments – 19. Specific References

Database Structure Catalog of properties and measurements Raw data, chemical & test descriptions Measurement presentation of data Derived from raw data Eg CI, particle size, histogram Tools for usage Eg how to ID excipients to solve problems User Interface

Database Features Cont.  With PharmHub we can: – Create online community of users to share information  i.e., gives us the ability to pool user excipient experiences and data  Discussion boards, forums etc.  Online lectures  Become the and Facebook ® of excipients? – Capture information in real time  Have the capability to gather product info. directly from manufactures production in real time – Blind information  Can put producers and usurer information in blinded from in database  Gives capability to correlate users and producer data, which is not done currently

Database Partners  Worked with individuals and organizations for database guidance – IPEC – Pharm IQ – Knowledgeable individuals in Pharma  Database sustainability

Presentation Style  We would like this to be interactive discussion not a lecture – Please feel free to interrupt at any time!!!  Can you…  What would happen if….  Can you show me….